Browse the evidence

L-aspartate may serve as a novel endogenous inducer of energy expenditure and suppressor of adipogenesis and lipogenesis along with activation of AMPK.

L-aspartate could be explored as a therapeutic agent for enhancing energy expenditure and reducing fat accumulation.

Higher adipose tissue GIP receptor mRNA expression is related to elevated glycerol release after GIP and GLP-1/GIP/glucagon receptor triagonist stimulation.

Increased GIP receptor expression may enhance fat mobilization, suggesting a focus for obesity treatments.

The engineered GLP-1 receptor agonist depot offers a more convenient and long-lasting therapeutic option for managing diabetes and treating metabolic disorders.

This approach could simplify treatment regimens for patients with diabetes.

Higher genetic GLP1R gene expression is associated with a lower risk of kidney disease progression (HR, 0.96; P = .02).

Practitioners may consider the role of GLP1R gene expression in managing kidney disease risk.

Higher GLP1R gene expression is associated with a small reduction in risk of kidney disease progression in fully adjusted models (HR, 0.96; P = .04).

This suggests that monitoring GLP1R gene expression could be relevant in kidney disease management.

Nutrients play a multifaceted role in cardiovascular health beyond their impact on cardiac events.

Practitioners should consider the diverse roles of nutrients in promoting cardiovascular health.

Dietary supplements may contribute to CVD risk reduction.

Incorporating dietary supplements may be beneficial for individuals at risk of CVD.

BGM1812 is a novel dual amylin and calcitonin receptor agonist with enhanced efficacy compared to petrelintide.

BGM1812 may be a promising option for obesity treatment.

BGM1812 exhibits excellent performance in terms of half-life, stability, and solubility.

These properties suggest BGM1812 could be a viable therapeutic option.

The interaction between hyperglycemia, endothelial dysfunction, inflammation, and thrombosis contributes to the progression of coronary artery disease (CAD) and its acute complications.

Understanding these interactions can help in developing targeted therapies for CAD.

GLP-1 receptor agonist patients had significantly lower serum albumin (4.06 g/dL) and prealbumin levels (23.52 mg/dL) compared to controls (4.22 g/dL and 25.55 mg/dL, respectively).

Monitoring nutritional status, including serum albumin and prealbumin, may be important for patients on GLP-1 receptor agonists.

Polar lipids (PL) in foods may play a key role in reducing inflammation.

Incorporating foods rich in polar lipids may help manage inflammation.

Obesity-related vasodilator dysfunction involves factors such as vascular insulin resistance, lipotoxicity, and visceral adipose tissue expansion.

Understanding these factors can guide targeted interventions for managing obesity-related vascular issues.

Rational protein engineering and delivery innovations transformed incretin biology into global metabolic therapeutics.

Innovations in protein engineering can enhance therapeutic efficacy.

Genetic variation within the leptin-melanocortin pathway may predict response to endoscopic interventions and guide personalized treatment selection.

Understanding genetic factors can help tailor obesity treatments to individual patients.

The study aims to understand the use of semaglutide for treating obesity and its pharmacological mechanism.

The study may provide insights into how semaglutide works, aiding in treatment decisions.

The use of nano-based medications through transdermal delivery is important for effective obesity treatment.

Practitioners should consider incorporating nano-based medications for better treatment outcomes.

Coconut oil and kernel flakes failed to induce favorable lipid changes comparable to coconut milk supplementation.

Coconut oil and kernel flakes may not be effective for improving lipid profiles compared to coconut milk.

The MC4R gene variant rs17782313 is directly associated with the risk of metabolic syndrome (MetS) in obese adults (B = 0.010; P = 0.023).

Genetic testing for the MC4R variant may help identify individuals at higher risk for metabolic syndrome.

Glycemic index (GI) and glycemic load (GL) mediate the relationship between the MC4R variant and LDL cholesterol (LDL-C) levels.

Dietary management focusing on GI and GL may help mitigate LDL-C levels in genetically susceptible individuals.

Mitochondrial uncoupling promotes energy dissipation and may serve as a strategy for obesity treatment.

Practitioners may consider mitochondrial uncoupling as a potential target for obesity interventions.

Metabolic drugs such as GLP-1-based therapies and SGLT2 inhibitors have benefits that extend beyond metabolic improvements into changes in chronic inflammation.

Practitioners should consider the anti-inflammatory potential of metabolic drugs in clinical settings.

The review discusses emerging therapeutic strategies for MASLD and its associated comorbidities.

Practitioners should stay informed about new treatment options for MASLD and its comorbidities.

Pharmacological classes of metabolic drugs have unexpected and often beneficial effects on cardiovascular outcomes.

Consider the use of metabolic drugs in managing cardiovascular health.